We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The bed-in-a-box section of the mattress market is wildly diverse these days, but as a mattress reviewer, one of the most frequent questions I'm asked is, "So what's the deal with Purple?" ...

The overall quant rating is not an average of the factor grades listed. Instead, it gives greater weight to the metrics with the strongest predictive value.

Get Pro-Level Earnings Insights Before the Market Moves In a court filing on Monday, the Department of Health and Human Services (HHS) challenged Vertex Pharmaceuticals Inc VRTX, defending its ...

At the forefront of Vertex's expansion into pain management is suzetrigine (VX-548), a novel drug candidate with the potential to revolutionize the treatment of pain.

Keith Speights has positions in Vertex Pharmaceuticals. The Motley Fool has positions in and recommends Vertex Pharmaceuticals. The Motley Fool has a disclosure policy. Why This Beaten-Down Growth ...

The most recent trading session ended with Vertex Pharmaceuticals (VRTX) standing at $416.96, reflecting a -1.72% shift from the previouse trading day's closing. The stock's performance was behind ...

Vertex Pharma is all-but synonymous with cystic fibrosis (CF) treatment but wants to diversify into new areas, including diabetes with a just-announced acquisition of Semma Therapeutics.

Adding one of these travel photos as your Zoom background takes way less time than getting through customs. Here's how it's done. Make sure you have Zoom virtual backgrounds enabled on your Zoom ...

NEW YORK, NY / ACCESSWIRE / January 15, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex Pharmaceuticals Incorporated ("Vertex Pharmaceuticals") (NASDAQ:VRTX ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...